Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine in MDD and Coronary Artery Disease
NCT02454426Phase 1Withdrawn
- Sponsor
- Thomas Jefferson University
- Start
- Apr 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vortioxetine in major depressive disorder (MDD), sponsored by Thomas Jefferson University. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 10 weeks. Planned start Apr 2016; status: withdrawn.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02454426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454426.